新华医疗公告称，公司原拟收购中帜生物36.1913%股权，于2024年12月30日通过相关议案。截至公告 日，《股份转让协议》约定的交割期限已过，经协商决定终止该协议。公司与部分交易对方签订《股份 转让协议之补充协议》，并向其他方发送《股份转让协议终止通知函》。因付款先决条件未达成，公司 未付款，收购终止不会对现有经营业绩及财务状况产生不利影响。 ...

Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [1] Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [1] - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [1] - The non-recurring net profit was 370 million yuan, reflecting a decline of 38.98% year-on-year [1] - In Q3 2025, the company recorded a single-quarter main revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year [1] - The single-quarter net profit attributable to shareholders was 48.59 million yuan, down 63.39% year-on-year [1] - The single-quarter non-recurring net profit was 37.66 million yuan, a decline of 71.77% year-on-year [1] - The company's debt ratio stands at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [1] - The gross profit margin is reported at 25.11% [1] Market Activity - As of February 5, 2026, Xinhua Medical's stock closed at 15.45 yuan, down 0.58% with a turnover rate of 0.96% [1] - The trading volume was 57,800 hands, with a total transaction amount of 89.46 million yuan [1] - On February 5, the net inflow of main funds was 563,100 yuan, accounting for 0.63% of the total transaction amount [1] - The net inflow of speculative funds was 2.8369 million yuan, representing 3.17% of the total transaction amount [1] - Retail investors experienced a net outflow of 3.4001 million yuan, which is 3.8% of the total transaction amount [1] Analyst Ratings - In the last 90 days, two institutions have given ratings for Xinhua Medical, both recommending an increase in holdings [2] - The average target price set by institutions in the past 90 days is 20.0 yuan [2]

证券代码：600587 证券简称：新华医疗 公告编号：临2026-008 山东新华医疗器械股份有限公司关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）全资子公司新华医疗康复产业（西 安）有限公司于近日收到陕西省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况 如下： 一、医疗器械注册证的具体情况 1、产品名称：四肢联动康复训练仪 2、注册证编号：陕械注准20262190001 3、注册人名称：新华医疗康复产业（西安）有限公司 4、注册人住所：陕西省西安市国际港务区港务大道99号中西部陆港金融小镇F座1901号 8、适用范围：适用于辅助提高四肢的肌力及协调性，改善关节活动度。 9、批准日期：2026-01-23 10、有效期至：2031-01-22 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至目前，国内同行业有18家公 司已取得同类产品的医疗器械注册证。 12、产品主要特点 基于机 ...

Buybacks and Shareholder Actions - Guizhou Moutai has repurchased a total of 416,900 shares, accounting for 0.0333% of its total share capital, with a total payment of 571 million yuan [1] - Contemporary Amperex Technology Co., Ltd. has repurchased 15,990,800 shares, representing 0.3628% of its total A-share capital, with a total transaction amount of 4.386 billion yuan [2] - SF Holding has repurchased 5,095,850 shares, which is 1.01% of its total share capital, with a total amount of approximately 2 billion yuan [10] - Wireless Media has seen its major shareholders reduce their stakes, with Wensheng Fund and its concerted parties reducing 4% of the total share capital [12] Corporate Actions and Financial Updates - Tai Ling Microelectronics announced that its second-largest shareholder, the National Integrated Circuit Industry Investment Fund, has reduced its stake from 6.95% to 5.97% by selling 2,321,300 shares [3] - Nape Mining has terminated its investment in Swiss Veritas Resources AG due to changes in delivery conditions, with no breach of contract [4] - Huangshan Tourism plans to invest approximately 530 million yuan in the construction of a hotel project, with a total building area of 79,178.15 square meters [8][9] - *ST Jinling's restructuring plan has been approved by the court, allowing the company to enter the execution phase of the plan [7] Performance and Sales - Country Garden reported a contract sales amount of approximately 2.21 billion yuan for January 2026, with a sales area of about 280,000 square meters [11] - Industrial Fulian has accumulated a total buyback fund of 247 million yuan as of January 31, 2026 [17] - Yutong Bus produced 2,167 vehicles in January 2026, a decrease of 15.35% year-on-year [17]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

山东新华医疗器械股份有限公司 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）全资子 公司新华医疗康复产业（西安）有限公司于近日收到陕西省药品监督管理局颁发的 《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：四肢联动康复训练仪 2、注册证编号：陕械注准 20262190001 3、注册人名称：新华医疗康复产业（西安）有限公司 证券代码：600587 证券简称：新华医疗 公告编号：临 2026-008 9、批准日期：2026-01-23 10、有效期至：2031-01-22 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至目 前，国内同行业有 18 家公司已取得同类产品的医疗器械注册证。 12、产品主要特点 基于机械机构将扶手和脚踏的运动实现联动，使四肢中仅靠一侧健肢的运动即 可带动四肢同步运动，从而辅助提高偏瘫、骨关节损伤等患者四肢的肌力、关节活 动度 ...

智通财经APP讯，新华医疗(600587.SH)公告，公司全资子公司新华医疗康复产业(西安)有限公司于近日 收到陕西省药品监督管理局颁发的《医疗器械注册证》，相关产品名称为：四肢联动康复训练仪。 ...

山东新华医疗器械股份有限公司 第十一届董事会第二十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重大 遗漏负连带责任。 一、董事会会议召开情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600587 证券简称：新华医疗 编号：临2026-004 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十一届董事会第二十五次会议于 2026年1月20日以书面或通讯方式通知全体董事，据此通知，会议于2026年1月30日在公司三楼会议室召 开。会议以现场与通讯相结合的方式召开，会议应到董事11名，实到11名，公司高级管理人员列席了会 议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于换选公司董事的议案》 公司董事李孝利先生因工作调动已向公司董事会提交了书面辞职申请，申请辞去公司第十一届董事会董 事职务，根据《公司法》、《上海证券交易所股票上市规则》及《公司章程》等有关规定，经公司第十 一届董事会提名，提名赵军先生为公司新任董事。 公司董事换选后，第十一届董事会由 ...

Group 1 - The core viewpoint of the article highlights that Xinhua Medical has focused its R&D expenses over the past three years on two main areas: medical devices and pharmaceutical equipment [1] - The company is pursuing core technology breakthroughs and product innovations in high-end, intelligent, and green directions, particularly in high-end radiotherapy and imaging equipment, infection control devices, minimally invasive surgical instruments and consumables, and high-end pharmaceutical formulation equipment [1] - Additionally, Xinhua Medical is expanding into cutting-edge areas such as rehabilitation intelligent equipment, continuously advancing product technology upgrades and international certifications to strengthen its core technological barriers [1]

（编辑 王雪儿） 证券日报网讯 1月30日，新华医疗在互动平台回答投资者提问时表示，公司在安哥拉的相关订单金额正 在稳步增长，直线加速器等高端设备产品正在与安哥拉当地医疗机构保持深度沟通，积极推进市场开发 工作。 ...